Biogen Seeking A Path Forward After Phase III Tofersen Study Fails In ALS

Ionis-Partnered Asset Developed For SOD1 Genetic Mutations

 
• By Mandy Jackson

The drug showed favorable but not significant trends across secondary endpoints, and greater efficacy in slower-progressing patients and those treated earlier in the disease, in a small subpopulation.

Illuminated oil lamp on fence along woodland path
Biogen will seek guidance from regulators and others that may illuminate a path forward for tofersen in ALS • Source: Alamy

More from Clinical Trials

More from R&D